Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
116,932,531
-
Total 13F shares
-
99,191,549
-
Share change
-
+2,519,023
-
Total reported value
-
$1,156,525,724
-
Put/Call ratio
-
79%
-
Price per share
-
$11.66
-
Number of holders
-
288
-
Value change
-
-$49,302,844
-
Number of buys
-
164
-
Number of sells
-
115
Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q4 2024
As of 31 Dec 2024,
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) was held by
288 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
99,191,549 shares.
The largest 10 holders included
ARK Investment Management LLC, BlackRock, Inc., VANGUARD GROUP INC, STATE STREET CORP, MORGAN STANLEY, REGENERON PHARMACEUTICALS, INC., Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Group, Inc., CITADEL ADVISORS LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
289
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.